Canada Markets closed

PFE Jan 2024 35.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
14.90-0.85 (-5.40%)
As of 12:51PM EST. Market open.
Full screen
Previous Close15.75
Open14.90
Bid14.60
Ask14.95
Strike35.00
Expire Date2024-01-19
Day's Range14.90 - 14.90
Contract RangeN/A
Volume3
Open Interest758
  • Motley Fool

    Better Buy: Novavax or BioNTech Stock?

    The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.

  • Reuters

    UPDATE 1-China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots

    CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech. As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines. The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology.

  • Reuters

    China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots

    CanSino Biologics CEO Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech. As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines. The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology.